1. Pink Sheet
  2. >>Vaccines

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

 
• By Bridget Silverman

As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.

'Dynamic Changes' In Pneumococcal Disease Incidence are Anticipated. • Source: Shutterstock

The active pipeline of new, higher-valent pneumococcal vaccine candidates promises to keep the US Centers for Disease Control and Prevention’s already notoriously confusing guidelines at the center of deliberations by its Advisory Committee for Immunization Practices.

Key Takeaways

  • The CDC’s Advisory Committee for Immunization Practices is preparing to vote on recommendations for Merck’s 21-valent V116 pneumococcal vaccine candidate at its 26-28 June meeting, less than two weeks after the vaccine’s 17 June FDA user fee goal.

  • Merck’s adult-specific pneumococcal conjugate vaccine strategy could support broader age-based PCV recommendations than the marketed vaccines, including an expected vote on 50-64-year-old adults without risk factors

The committee now is gearing up for a vote at its 26-28 June meeting on recommendations for Merck & Co., Inc.'s adult-specific 21-valent pneumococcal conjugate vaccine V116, also known as PCV21

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.